Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics and pharmacodynamics of a long-acting monoclonal antibody against malaria in African adults.

The Journal of clinical investigation·2026
Same author

Correlation Between Renal Biomarkers, Glomerular Filtration Rate, and Meropenem Clearance in Pediatric Septic Shock.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same author

Room-Temperature Viscoelastic Liquid Semiconducting Block Copolymer with Mixed Ionic-Electronic Conduction.

Journal of the American Chemical Society·2026
Same author

VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines.

Science translational medicine·2026
Same author

Rapid Optimization Enabled by Single-Molecule Tracking: Discovery of a Potent RUVBL1/2 Inhibitor to Evaluate the Targeting of MYC-Driven Cancers.

Journal of medicinal chemistry·2026
Same author

Transforming long-term post-acute care for the aging population through home infusion therapy in China: assurance for quality and safety of care delivery (Part 2).

Frontiers in public health·2026

Related Experiment Video

Updated: May 14, 2026

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

Improved vancomycin dosing in children using area under the curve exposure.

Jennifer Le1, John S Bradley, William Murray

  • 1Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093-0714, USA. jenle@ucsd.edu

The Pediatric Infectious Disease Journal
|January 24, 2013
PubMed
Summary

Vancomycin dosing in children requires higher doses (60-70 mg/kg/day) to achieve therapeutic area under the curve/minimum inhibitory concentration (AUC/MIC) targets. Trough concentrations are less reliable for vancomycin efficacy in pediatric patients.

More Related Videos

Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS
08:24

Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS

Published on: January 23, 2026

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
11:28

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Published on: September 9, 2015

Related Experiment Videos

Last Updated: May 14, 2026

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS
08:24

Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS

Published on: January 23, 2026

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
11:28

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Published on: September 9, 2015

Area of Science:

  • Pharmacology
  • Pediatric Infectious Diseases
  • Clinical Pharmacy

Background:

  • Vancomycin is a critical antibiotic for treating serious Gram-positive infections in children.
  • Optimizing vancomycin dosing in pediatric populations is essential for effective treatment and minimizing resistance.
  • Current dosing strategies may not consistently achieve therapeutic targets in children.

Purpose of the Study:

  • To determine vancomycin pharmacokinetic indices in pediatric patients.
  • To compare the attainment of two target exposures: AUC/MIC ≥400 and trough concentration ≥15 mcg/mL.
  • To inform optimal vancomycin dosing regimens for children.

Main Methods:

  • Population-based pharmacokinetic modeling using NONMEM 7.2.
  • Analysis of vancomycin serum concentrations from 702 pediatric patients (≥3 months old).
  • Monte Carlo simulations (N=11,000) to evaluate dosing regimens and target attainment.

Main Results:

  • Developed pharmacokinetic models for vancomycin clearance and volume of distribution based on age, weight, and creatinine.
  • Initial median vancomycin dose (44 mg/kg/day) was inadequate for most subjects.
  • Doses of 60-70 mg/kg/day achieved target AUC/MIC in ~75% of simulated pediatric subjects.

Conclusions:

  • Vancomycin area under the curve to minimum inhibitory concentration (AUC/MIC) is a more reliable target than trough concentrations in children.
  • Higher vancomycin dosages (60-70 mg/kg/day) are necessary to achieve target AUC/MIC ≥400 in approximately 75% of pediatric patients.
  • Individualized vancomycin dosing adjustments based on age, creatinine, and MIC are crucial for pediatric patients.